Search:
Pharmaceutical Contract Manufacturing Company
 

 
   
 

News & Events

Welcome to Dalton Pharma Services News and Events section. On this page you will find our current and past news releases, and a list of event happenings. If you can't find what you are looking for, please contact us and we will be happy to provide you with assistance.

 
 

 
 


News And Events

7/8/2014 Dalton and GLyPharma Enter Into Aseptic Filling Services Agreement
Dalton Pharma Services signs agreement with GLyPharma Therapeutics Inc., to provide aseptic fill/finish services and analytical services for FE 203799 for cancer patients.
5/8/2014 Dalton Announces U.S. FDA Approval of Clinical Trial Plan for Vaccine Against Campylobacter jejuni
Client Phase I clinical trial plan utilizing Dalton manufactured cGMP sterile conjugated vaccine approved by U.S. FDA.
3/31/2014 Dalton Announces Renewal of Award from NIDA of NIH to Fund Research
Dalton Medicinal Chemistry receives notice of award from NIDA of NIH to fund research of novel series of compounds to treat drug abuse and alleviate pain.
3/20/2014 Dalton Pharma Services Announces Completion of a Major Expansion in Aseptic Filling Capabilities
Dalton announces the completion of a $2.5 million expansion of its sterile and aseptic filling capabilities.
12/3/2013 Dalton Announces Release of White Paper on Risk Sharing
Dalton releases white paper on risk sharing in sponsor-CMO relationships.
4/10/2013 Cyclica and Dalton Announce Collaboration Agreement to Identify and Develop New Drug Candidates
Cyclica and Dalton announce collaboration agreement to identify and develop new drug candidates applying advanced computational molecular design to medicinal chemistry and drug development approaches.
3/27/2013 Dalton Receives Notice of Award from NIDA of NIH to Fund Research
Dalton Medicinal Chemistry receives notice of award from NIDA of NIH to fund research of novel series of compounds to treat drug abuse and alleviate pain.
1/29/2013 Dalton Announces Sterile Filling Expansion Plan
Dalton announces strategic aseptic filling expansion plan. The plan adds capabilities and upgrades to support the growing needs of its customers for sterile filling.
11/30/2012 Dalton Announces Addition of SEC-MALS Large Molecule Testing Services
Dalton adds SEC-MALS large molecule testing capability. This specialized testing capability allows for more accurate measurement of large molecular weight products.
10/31/2012 Dalton to Attend Bio Europe 2012 and Expand European Customer Base
Dalton to attend BIO Europe 2012 in Hamburg, Germany held November 12-14, 2012. The conference hosts key pharmaceutical and biotechnology companies from across Europe and beyond. Dalton is well positioned to assist innovative European drug companies achieve their strategic goals and will strengthen existing relationships while attending.
9/28/2012 Dalton and University of Guelph Collaborate in Anti-TB Vaccine Development
Dalton and University of Guelph are collaborating on the development of an anti-tuberculosis (TB) vaccine. The vaccine is being developed jointly by Professor Mario A. Monteiro and Dalton Pharma Services in Canada.
7/24/2012 Dalton Pharma Services Supports Client Milestone in Dengue Treatment Clinical Trial
A Phase 1b clinical trial to evaluate Celgosivir as a treatment against Dengue Fever has opened for enrolment at the Singapore General Hospital. Dalton Pharma Services has successfully completed a comprehensive drug development program for the CELADEN trial, which included Celgosivir process development, cGMP API and capsule manufacturing in support of Duke-NUS’s translational clinical research program.
6/14/2012 Dalton Pharma Services and Clarity Pharmaceuticals Enter Into Manufacturing Services Agreement
Dalton will provide cGMP chemistry manufacturing, scale up, aseptic fill/finish services and analytical support for Clarity
6/11/2012 Dalton Pharma Services Receives GLP Certification
Dalton Announces it has received a Good Laboratory Practices (GLP) certificate from The Standards Council of Canada (SCC)
4/24/2012 Dalton Announces Collaboration Developing a Promising Broad Spectrum Antiviral Agent
Dalton signs manufacturing agreement for a potent antiviral agent that has shown to be effective in animal studies against avian influenza virus, ebola and alphavirus infections.
12/30/2011 Dalton Pharma Services Announces New Enhancement to its Website
Dalton Announces Online Structure Search Capability
11/30/2011 Dalton Pharma Services Announces a Successful Health Canada Audit
Dalton Announces a Successful Repeat Health Canada Audit of it’s cGMP Manufacturing and Testing Facilities
10/5/2011 Dalton Pharma Services and The Henry M. Jackson Foundation Announce a Services Agreement for the Advancement of Military Medicine
Dalton Enters Into cGMP Vaccine and Conjugation Aseptic Fill Services Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine
9/22/2011 Dalton Pharma Services Exhibits at the 2011 Contracting & Outsourcing Conference and Exhibition in New Jersey
Dalton Pharma Services, today announced the Company is scheduled to present at the 10th Annual Contract Pharma, Contracting & Outsourcing Conference and Tabletop Exhibition on Sep 22nd, from 10 am to 4 pm.
9/12/2011 Dalton Pharma Services Attending ChemOutsourcing in New Jersey
Dalton Pharma Services today announced that the Company is scheduled to attend ChemOutsourcing, an annual pharmaceutical chemistry conference in Long Branch, New Jersey.
5/16/2011 Dalton and Zafgen Enter Into Aseptic Fill Services Agreement
Dalton Pharma Services announced that it has entered into a Aseptic Fill Manufacturing Services Agreement with Zafgen Inc.
2/3/2011 Dalton Founder Supports the Commercialization of Innovation at Launch of York Regional Innovation Centre
The Ontario Network of Excellence (ONE) is a collaborative network of regional innovation centres across Ontario, and is an important part of the aggressive innovation agenda to ensure that the Province will continue to flourish in the fiercely competitive global marketplace.
2/3/2011 Dalton and Oncovir Enter Into API Manufacturing & Aseptic Fill Services Agreement
Dalton Pharma Services today announced the company has entered into an API Manufacturing & Aseptic Fill Services Agreement with Oncovir Inc.
1/10/2011 Dalton and AdeTherapeutics enter into an Anti-Adhesion (Scar Tissue Reduction) Manufacturing Services Agreement
Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Clinical Manufacturing Services Agreement with AdeTherapeutics (ā day’ therapeutics), Inc., a specialty pharma company based in Saskatoon, Saskatchewan, focused on providing quality therapeutic options in inflammation and acute care medicine.
11/25/2010 Dalton Becomes a Bronze Sponsor for Healthcare & Biotechnology Venture Challenge
Dalton Pharma Services Announces Bronze Sponsorship for the 2010 Healthcare & Biotechnology Venture Challenge.
11/22/2010 Dalton Announces Contract Chemistry Services and Manufacturing Agreement with Lonza
Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.
10/7/2010 Off Shoring Pharma R&D; Value or Cheap
Upheaval in the pharmaceutical industry of off shoring pharma is causing a massive shift of R&D from North America to China and India.
2/1/2010 Dalton Announces Successful Completion of Health Canada Inspection
Dalton Announces Successful Completion of Health Canada Inspection and Compliance with European Directive for Manufacture and Testing of Drug Products Imported to the European Union.
10/29/2009 BIKAM and Dalton Medicinal Chemistry Expand and Renew Research Agreement
BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics.
9/21/2009 Dalton Pharma Services Adds Formulation Development Services
Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.
5/11/2009 Dalton and ProCitius Announce Strategic Alliance to Provide Contract Chemistry Services
Dalton Pharma Services and ProCitius Research jointly announce a strategic alliance created to provide clients with contract chemistry services of exceptional value.
3/23/2009 Dalton and BioRelix Announced Expansion to Discover and Develop New Therapeutics
BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.
2/23/2009 Dalton and Boehringer Announce Renewal Chemistry Services Agreement
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs.
10/22/2008 Dalton Pharma Services and Myelin Repair Foundation Enter into Chemistry Collaboration
The Myelin Repair Foundation and Dalton Pharma Services jointly announce a chemistry collaboration to develop new potential therapeutic compounds for myelin degradation disease states such as Multiple Sclerosis (MS).
7/15/2008 Dalton Pharma Services Expands its Contract Analytical Services
Dalton Pharma Services is pleased to announce the expansion of its Contract Analytical Services with the commissioning of two validated LC-MS/MS instruments which have been qualified for GMP testing of pharmaceutical products.
5/6/2008 Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides
Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.
5/3/2008 BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.
1/23/2008 Dalton Medicinal Chemistry Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd
Dalton Medicinal Chemistry Partners is utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd.
1/22/2008 Funding Boost for Innovative VacciMax Platform
Canadian vaccine specialist ImmunoVaccine Technologies (IVT) has scored a multi-million dollar grant to go towards developing its potent immune enhancement systems.
11/13/2007 BioRelix and Dalton jointly announced a research collaboration to discover new therapeutics.
Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.
10/27/2007 Dalton Medicinal Chemistry Partners Achieves Milestone with Boehringer Ingelheim Ltd.
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed amount.
6/14/2007 Dalton and X-GEN Pharmaceuticals enter into a Manufacturing Services Agreement
Dalton enters into a long term Manufacturing Services Agreement with X-GEN Pharmaceuticals, Inc., a specialty pharma company based in Big Flats, New York, focused on providing quality therapeutic options in both specialized disease areas and broad range treatment choices.
5/23/2007 Dalton Partners & Boehringer Ingelheim (Canada) Ltd. enter into a Medicinal Chemistry Services Agreement
Dalton Medicinal Chemistry Partners will utilize their medicinal chemistry services expertise to design and synthesize novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
3/1/2007 Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into an Agreement.
Affectis has contracted Dalton for the manufacturing of preclinical tox material with potential for cGMP production.
1/26/2007 Dalton Announces Successful Completion of Health Canada Inspection.
A Positive rating from regulatory agency clears way for delivery of commercial products to clients of the Company’s Drug Manufacturing services.
8/31/2006 Dalton Pharma Services Launches Expanded Medicinal Chemistry Services
Dalton Pharma Services announces the formation of Dalton Medicinal Chemistry Partners, a joint venture with Dr. Judd Berman. The joint venture now offers expanded, mechanism based medicinal chemistry services to companies involved in drug discovery.
4/12/2006 Dalton Announces Completion of GMP Oligonucleotide Manufacturing Facility
Dalton Pharma Services, provider to leading pharmaceutical companies, today announced the completion of its state-of-art Oligonucleotide Production Suite.
3/31/2005 Dalton Announces Operating Name Change
Dalton Chemical Laboratories Inc. is proud to announce that they will now be operating as Dalton Pharma Services.
10/25/2004 Dalton Chemical Labs Inc. Completes it's $1.4 Million Expansion to it's Facilities.
Dalton Chemical Laboratories, Inc., a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced it has completed Phase III of its facilities expansion.